Navigation Links
Drug Treatment Market For Obesity Will Increase More Than Five-Fold, Reaching $2.7 Billion in 2016
Date:3/25/2008

Growth Will Be Driven by Novel Emerging Therapies, Including Drugs from

Arena and Amylin, According to a New Report from Decision Resources

WALTHAM, Mass., March 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the obesity drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan will experience more than five-fold growth, rising from $478 million in 2006 to more than $2.7 billion in 2016. The market will grow most rapidly in the United States, where sales will increase from $222 million in 2006 to nearly $2 billion in 2016.

The new Pharmacor report entitled Obesity finds that the significant market growth will be driven by a number of emerging therapies, including Arena Pharmaceuticals' lorcaserin and Amylin Pharmaceuticals' pramlintide/leptin combination, which are both expected to launch in the world's major pharmaceutical markets by 2011. Lorcaserin, pramlintide/leptin and other emerging novel therapies will capture 80% of the total obesity market in 2016 as physicians switch from the few currently available therapies to new treatments with novel mechanisms of action.

The report also finds that increasing concern of the Food and Drug Administration (FDA) regarding the long-term safety of drug treatments for chronic conditions such as obesity poses one of the most significant threats to companies developing anti-obesity drugs. For example, although Sanofi- Aventis's Acomplia (rimonabant) had been widely anticipated to become a key therapy for obesity, its blockbuster potential was eliminated after a negative opinion of the drug was issued by an FDA advisory panel last year. According to the report, similar safety concerns will plague Merck's taranabant and Pfizer's CP-945598, which belong to the same drug class as rimonabant.

"Given the high prevalence of obesity in the world's major pharmaceu
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Cancer treatments in phase 3 trials successful up to half of the time
2. FSU researchers mutant proteins could lead to new treatment for heart disease
3. WellPoints Health Plans to Cover Newly Approved Cancer Treatment
4. TB Drug Treatment Can Lead to Severe Pneumonia
5. Youth sports concussion program points to need for proper treatment of concussion in children
6. Prostate size and other neglected factors influence prostate cancer treatment satisfaction
7. Quality of Life an Issue in Prostate Cancer Treatment
8. Molecular biology of sleep apnea could lead to new treatments
9. One-Third of U.S. Primary Care Physicians and Cardiologists Do Not Currently Prescribe Treatment to Meet HDL Cholesterol Targets as Recommended By National Guidelines
10. Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments
11. Arizona Senate Approves Smoking Cessation Treatments for State Medicaid Beneficiaries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)Wind Turbines are popping up in the most unusual places, and to do everything from growing mushrooms, making wine to keeping prisoners in jail! , (PRWEB) December 5, 2009 -- W
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)ANAHEIM, Calif., Dec. 4 Pamela Bowen, Chief Information Officer at Crescent Healthcare, was selected as a finalist for the "Chief Innovation Officer" Appy Award for transforming Crescent,s business w
(Date:12/4/2009)Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accuratel
(Date:12/4/2009)Outcomes same whether procedure done immediately or 3 weeks later, study shows , , FRIDAY, Dec. 4 (HealthDay News) -- Timing of surgical repair or reconstruction of multiple-ligament knee inju
Breaking Medicine News(10 mins):Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2
...duces personality types used frequently in consume...e are motivated by one of two fundamental needs: t... that will help them achieve hopes and aspirations... exercise self-control when they choose goal-pursu...
...ervice to Retail Markets, MUNDELEIN, Ill., Jan. 2...day the retail launch of its headline-making,salad...e will consist of Z Trim Ranch, Z,Trim Honey Dijon...ht to transfer some of our success from Z,Trim pro...
...special needs child, Chelle Brewer,s, story of tri...spouse alpha moms worl...ewer,s soldier,husband is nearing the end of a hal...a heart. She volunteers for the,USO, Soldier,s Lis...
...s that seem to influence outcome , , WEDNE...ns that predict patient response to the two common...a) and venlafaxine (Effexor) have been identified ...protein called P-gp, which removes drugs and other...
...ap or press a surface is essential for everyday li...y or an iPhone. But researchers at the University...ivial action is the result of a complex neuro-moto...omedical engineer Francisco Valero-Cuevas is worki...
...ef, researchers say , , WEDNESDAY, Jan. 23... back pain, non-steroidal anti-inflammatory drugs ...e effective than acetaminophen. , That,s the concl...SAIDs are "slightly effective" for short-term symp...
Other Medicine News:Health News:Your personality type influences how much self-control you have 2Health News:Z Trim Holdings, Inc. Launches Innovative Retail Line of Lower Fat Salad Dressings in Upscale Grocery Chain 2Health News:Z Trim Holdings, Inc. Launches Innovative Retail Line of Lower Fat Salad Dressings in Upscale Grocery Chain 3Health News:'Military Spouse of the Year 2008' Announced 2Health News:Genetics May Determine Antidepressants' Effectiveness 2Health News:What gives us fingertip dexterity? 2Health News:What gives us fingertip dexterity? 3Health News:NSAIDs No Better for Low Back Pain 2
(Date:12/4/2009)INDIANAPOLIS, Dec. 4 The U.S. Food and Drug Administration (FDA) today approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes
(Date:12/4/2009)Workers Ensure Emergency Deliveries are Transported ,, PHILADELPHIA, Dec. 4 Teamster members employed by the Philadelphia chapter of the American Red Cross are hard at work educating the public abo
(Date:12/4/2009)DURHAM, N.C., Dec. 4 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today announced that the first patient has been enrolled in the company,s Phase II-b, dose escalation, clinical trial in S
Breaking Medicine Technology:FDA Approves Lilly's Zyprexa for Two Adolescent Indications 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 3FDA Approves Lilly's Zyprexa for Two Adolescent Indications 4FDA Approves Lilly's Zyprexa for Two Adolescent Indications 5FDA Approves Lilly's Zyprexa for Two Adolescent Indications 6FDA Approves Lilly's Zyprexa for Two Adolescent Indications 7Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 1Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 2Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 3Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 4Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 5Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 6Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 7Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 8Gene Mutation Could Be Key to Rare Blood Vessel Disease 52456 1Gene Mutation Could Be Key to Rare Blood Vessel Disease 52456 2Gene Mutation Could Be Key to Rare Blood Vessel Disease 52456 3Global One Consulting Announces Exclusive Contract to Expand Saigene Biotech Inc Sales in Emerging Markets 13155 1Global One Consulting Announces Exclusive Contract to Expand Saigene Biotech Inc Sales in Emerging Markets 13155 2Global One Consulting Announces Exclusive Contract to Expand Saigene Biotech Inc Sales in Emerging Markets 13155 3
...d Muscle Society International Congress, SOUTH PL...TC), a biopharmaceutical company focused on the di...l-molecule drugs targeting,post-transcriptional co...from a Phase 2 clinical trial of PTC124 in patient...nonsense mutation. The results, which include data...
... Trial Results of First Pro-Healing Stent Also ...ONG KONG, Oct. 18 OrbusNeich,s Genous(TM),Bio-eng...ions about,innovation in interventional cardiology...catheter Cardiovascular Therapeutics symposium, TC...on Convention Center in,Washington, D.C. The line...
Other Medicine Technology:PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 2PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 3PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 4OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007 2
... allows the physician to intubate the canaliculi i...anesthetic drops., ,The SRS is made of medical...25mm, 30mm and 35mm (disposable sizers sold separa...d head to provide fixation. Each head consists of ...
...s a peptide highly dependent on growth hormone and...ansported in serum by several IGF-binding proteins...ts of IGF-I are a useful adjunct to assessment of ... IGF-I concentration is strong evidence against GH...
...ystem built around the many positive attributes ,...of Logic Driven Incubation (LDI). LDI technology ,...ance with the fastest possible incubation times. ,...iac biomarkers and HCG to be run in around 15 ,m...
ACS:180 C-Peptide Assay
Medicine Products: